Inmed Pharmaceuticals Inc. (IMLFF) 0.1150 $IMLFF
InMed Pharma's Hiring of Tiberend Highlights Biotech Focus
ACCESSWIRE - Wed Dec 03, 9:32AM CST
WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc (NASDAQ: GWPH) and others conducting clinical trials targeting important indications like cancer pain and arthritis, the data collected so far has suggested that cannabinoids could have far-reaching beneficial effects on the human body.
ADXS: 7.57 (+0.50), GWPH: 68.08 (+1.82), GALE: 1.49 (-0.02)
InMed Pharmaceuticals, Inc. Retains Tiberend Strategic Advisors, Inc. as Its Investor Relations and Corporate Communications Counsel
Marketwired - Tue Dec 02, 5:02AM CST
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems, today announced that it has retained Tiberend Strategic Advisors, Inc. to manage its investor and corporate communications programs. Tiberend Strategic Advisors is a New York City-based full service strategic communications firm focused on serving publicly traded and emerging growth companies in the healthcare and life sciences industry.
Cannabis Stocks Move Lower as Mid-terms Approach
ACCESSWIRE - Tue Nov 04, 8:02AM CST
Whitefish, MT / November 4, 2014 / Cannabis stocks moved lower last week and early this week, according to data from the Marijuana Index(TM). Top gainers included Endexx Corporation (OTC: EDXC), which is trading up more than 35% since last Monday, despite having no recent press releases. Industry bellwethers like GW Pharmaceuticals plc (NASDAQ: GWPH) were trading largely even for the week, as of mid-day trading on Monday.
GWPH: 68.08 (+1.82), MGW.VN: 0.040 (unch)
InMed Pharma: Proprietary Platform, Growing Pipeline, Low Valuation
ACCESSWIRE - Wed Oct 29, 9:01AM CDT
Whitefish, MT / ACCESSWIRE / October 29, 2014 / The U.S. medical cannabis industry has grown at a 16.2% CAGR between 2009 and 2014 to reach $2 billion in annual revenue, according to IBISWorld. Driven by both favorable legalization and clinical studies, the analyst expects demand for the industry's products to continue growing in the five years to 2019. Investors have been taking note of these growth rates and have many opportunities.
GWPH: 68.08 (+1.82)
InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Thu Oct 23, 5:02AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF) announces it has has formed an exclusive strategic collaboration with Dr. Vikramaditya Yadav of the Department of Chemical and Biological Engineering at the University of British Columbia to develop a targeted drug delivery system.
Cannabis Technologies Inc. Now Trading as InMed Pharmaceuticals Inc.
Marketwired - Tue Oct 21, 5:01AM CDT
InMed Pharmaceuticals ("InMed" is pleased to announce the completion of its name change and effective immediately will no longer be trading as Cannabis Technologies Inc. InMed has commenced trading under the stock symbols (CSE: IN) and (OTCQB: IMLFF).
InMed Pharma's Hiring of Tiberend Highlights Biotech Focus
ACCESSWIRE - Wed Dec 03, 9:32AM CST
WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc (NASDAQ: GWPH) and others conducting clinical trials targeting important indications like cancer pain and arthritis, the data collected so far has suggested that cannabinoids could have far-reaching beneficial effects on the human body.
ADXS: 7.57 (+0.50), GWPH: 68.08 (+1.82), GALE: 1.49 (-0.02)
InMed Pharmaceuticals, Inc. Retains Tiberend Strategic Advisors, Inc. as Its Investor Relations and Corporate Communications Counsel
Marketwired - Tue Dec 02, 5:02AM CST
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems, today announced that it has retained Tiberend Strategic Advisors, Inc. to manage its investor and corporate communications programs. Tiberend Strategic Advisors is a New York City-based full service strategic communications firm focused on serving publicly traded and emerging growth companies in the healthcare and life sciences industry. Cannabis Stocks Move Lower as Mid-terms Approach
ACCESSWIRE - Tue Nov 04, 8:02AM CST
Whitefish, MT / November 4, 2014 / Cannabis stocks moved lower last week and early this week, according to data from the Marijuana Index(TM). Top gainers included Endexx Corporation (OTC: EDXC), which is trading up more than 35% since last Monday, despite having no recent press releases. Industry bellwethers like GW Pharmaceuticals plc (NASDAQ: GWPH) were trading largely even for the week, as of mid-day trading on Monday.
GWPH: 68.08 (+1.82), MGW.VN: 0.040 (unch)
InMed Pharma: Proprietary Platform, Growing Pipeline, Low Valuation
ACCESSWIRE - Wed Oct 29, 9:01AM CDT
Whitefish, MT / ACCESSWIRE / October 29, 2014 / The U.S. medical cannabis industry has grown at a 16.2% CAGR between 2009 and 2014 to reach $2 billion in annual revenue, according to IBISWorld. Driven by both favorable legalization and clinical studies, the analyst expects demand for the industry's products to continue growing in the five years to 2019. Investors have been taking note of these growth rates and have many opportunities.
GWPH: 68.08 (+1.82)
InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Thu Oct 23, 5:02AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF) announces it has has formed an exclusive strategic collaboration with Dr. Vikramaditya Yadav of the Department of Chemical and Biological Engineering at the University of British Columbia to develop a targeted drug delivery system. Cannabis Technologies Inc. Now Trading as InMed Pharmaceuticals Inc.
Marketwired - Tue Oct 21, 5:01AM CDT
InMed Pharmaceuticals ("InMed"
is pleased to announce the completion of its name change and effective immediately will no longer be trading as Cannabis Technologies Inc. InMed has commenced trading under the stock symbols (CSE: IN) and (OTCQB: IMLFF). 
